Design Therapeutics (DSGN) vs Obsidian Therapeutics (OBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Obsidian Therapeutics is the larger company by market cap ($756.1 million vs $719.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DSGN | OBX |
|---|---|---|
| Share price | $11.49 | $12.24 |
| Market cap | $719.06M | $756.10M |
| 1-day change | -1.71% | -7.27% |
| YTD return | +22.49% | — |
| 1-year return | +65.56% | — |
| 5-year return | -19.37% | — |
| EPS (TTM) | $-1.18 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.25 | $49.97 |
| 52-week low | $5.28 | $12.07 |
| Distance from 52-week high | -33.39% | -75.51% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +88.95% | +218.63% |
| Average volume | 604.06K | 367.35K |
| Shares outstanding | 62.58M | 61.77M |
| Employees | 55 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Design Therapeutics
DSGN stock →Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Obsidian Therapeutics
OBX stock →Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
DSGN vs OBX FAQ
Which is bigger, Design Therapeutics or Obsidian Therapeutics?
Obsidian Therapeutics (OBX) is larger, with a market capitalization of $756.10M compared with $719.06M for Design Therapeutics (DSGN).
Are Design Therapeutics and Obsidian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.